Portfolio

Rigontec

Exit

Rigontec GmbH, is a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases.

Rigontec focus on the development of synthetic ligands of a novel receptor of the innate immune system, Retinoic acid Inducible Gene I (RIG-I), which recognizes viral RNA. RNA motifs that activate RIG-I promote the destruction of diseased cells and the induction of a lasting immune memory thereby treating and preventing recurrence of disease.

Rigontec’s, a proprietary first-in-class product targeting RIG-I, is currently being evaluated for development in several cancer types including melanoma and prostate cancer. ImOl100 is a chemically synthesized mimic of the natural ligand of RIG-I with improved safety and drug like properties. In various preclinical models, ImOl100 has demonstrated substantial tumor regression and systemic anti-tumor activity including long-term protection against tumor rechallenge. Rigontec’s technology also allows the design of pipeline candidates with additional gene silencing and inhibitory activities. Rigontec is financed by top-tier VC investors and is seeking to realize the full potential of its technology by developing an internal pipeline into the clinic.

Pressemeldungen

Rigontec Raises Additional €15M in Extended Series A to Advance Novel RIG-I Targeted Immuno-Oncology Therapeutics

Rigontec, the leader in RIG-I targeting RNA therapeutics, today announced that it has secured EUR 15 million in a third and final closing of its Series A round. The financing represents additional capital from current investors Boehringer Ingelheim Venture Fund, Forbion Capital Partners, High-Tech Gründerfonds…
Read

Rigontec GmbH raises €4.8m in a second closing of its Series A financing

Brings Series A total to €14.25m to advance RNA-based immunotherapeutics for cancer and viral diseases Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces it has raised €4.8 million in a second closing of…
Read

Rigontec GmbH raises € 9.45 m in a first closing of a Series A financing round to advance RNA-based immunotherapeutics for cancer and viral diseases

Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announces the first closing of its Series A financing round, raising €9.45 million. The round was co-led by Wellington Partners and Boehringer Ingelheim Venture Fund, and…
Read

Info & Contact

Dr. Annegret de Baey-Diepolder
Phone:
+49 8341 9993464
Web:
www.rigontec.de

Address

Biomedizinisches Zentrum, Gebäude 344
Sigmund-Freud-Str. 25
53127 Bonn

In portfolio

13. Jun 2014 – 06. Sep 2017
Exit